Gene: JAK2
Official Full Name: Janus kinase 2provided by HGNC
Gene Summary: This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO00569 | JAK2 Knockout cell line (HeLa) | Human | JAK2 | 1:3~1:6 | Negative | Online Inquiry |
KO11240 | JAK2 Knockout cell line (HCT 116) | Human | JAK2 | 1:2~1:4 | Negative | Online Inquiry |
KO11241 | JAK2 Knockout cell line (HEK293) | Human | JAK2 | 1:3~1:6 | Negative | Online Inquiry |
KO11242 | JAK2 Knockout cell line (A549) | Human | JAK2 | 1:3~1:4 | Negative | Online Inquiry |
JAK2 Gene Knockout Cell Lines are specialized cellular models that have been genetically engineered to disrupt the expression of the Janus kinase 2 (JAK2) gene, a critical component in the signaling pathways that mediate various biological processes, including hematopoiesis and immune response. These knockout cell lines serve as valuable tools for studying the role of JAK2 in cellular functions and disease pathology, particularly in myeloproliferative neoplasms and other disorders associated with aberrant JAK2 signaling.
The primary function of JAK2 in the cell revolves around mediating cytokine signaling through the activation of downstream effector pathways, such as the STAT (signal transducer and activator of transcription) pathway. By utilizing these knockout cell lines, researchers can comprehensively investigate the consequences of JAK2 deficiency, allowing for a deeper understanding of its role in essential cellular processes, signal transduction dynamics, and associated pathological effects.
In both research and clinical settings, these models are invaluable for drug discovery and development, particularly in identifying novel therapeutic targets for diseases linked to JAK2 mutations, such as polycythemia vera and essential thrombocythemia. The specificity of the knockout facilitates elucidation of JAK2-driven mechanisms, supporting the development of effective inhibitors that can selectively abrogate JAK2 and related pathways.
Compared to alternative models, the JAK2 Gene Knockout Cell Lines offer distinct advantages by providing a more precise experimental system with fewer confounding variables. Their use enables reproducible results in various assays, enhancing the rigor of experimental design and outcomes.
For researchers and clinicians focused on hematological cancers or immune system modulation, these cell lines present an unparalleled opportunity to advance scientific understanding and therapeutic advancements. By integrating the complexities of gene knockout technology with the study of JAK2 functionality, users can capitalize on insights that lead to innovative treatment strategies.
Our company prides itself on delivering high-quality, scientifically validated biological products and has extensive expertise in developing reliable genetic models that facilitate groundbreaking research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.